Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 6/20 | 0.46 |
| ▸ | FGF1 | P05230 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360450 | 0.85 | P2RY14 (0.39) | LGALS8 | |
| SCHEMBL22393 | 0.81 | SMPD1 (0.40) | — | |
| Pyrophosphoric Acid SCHEMBL7582145 | 0.80 | SMPD1 (0.39) | — | |
| SCHEMBL30007287 | 0.80 | SMPD1 (0.39) | — | |
| SCHEMBL7856353 | 0.80 | LGALS8 (0.50) | LGALS8FGF1 | |
| SCHEMBL118472 | 0.80 | LGALS8 (0.47) | LGALS8FGF1 | |
| SCHEMBL29656742 | 0.79 | P2RY14 (0.47) | — | |
| SCHEMBL3360274 | 0.79 | P2RY14 (0.47) | — | |
| SCHEMBL7541384 | 0.78 | P2RY14 (0.49) | — | |
| SCHEMBL7541741 | 0.78 | P2RY14 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155334-A1 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | UNIVERSITÉ DE STRASBOURG (FR) | 2014-06-05 | — | — | US | claimed |
| US-20140088036-A1 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | UNIVERSITE DE STRASBOURG (FR) | 2014-03-27 | — | — | US | claimed |
| US-20210361680-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NORMOXYS INC (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3787634-A1 | INOSITOL-BASED IMMUNOTHERAPIES | NormOxys, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20160067267-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2015138916-A1 | MYO-INOSITOL TRISPYROPHOSHATE AS AN ANTI-DIABETIC AGENT | NICOLAU YVES CLAUDE (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20140155334-A1 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | UNIVERSITÉ DE STRASBOURG (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140088036-A1 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | UNIVERSITE DE STRASBOURG (FR) | 2014-03-27 | — | — | US | disclosed |
| EP-2621273-A2 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | Normoxys, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012045009-A2 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | NORMOXYS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155334-A1 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | PPIP5K2, INPP5A, INPP5B | LGALS8 2498/4885FGF1 2368/4885 |
| US-20140088036-A1 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES | PPIP5K2, INPP5A, INPP5B | LGALS8 2498/4885FGF1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.